BioAtla, Inc. cotiza a 1.25 USD y tiene una capitalización bursátil de $2M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating…
| Periodo | 2026-08 | 2025-11 | 2025-08 | 2025-05 |
|---|---|---|---|---|
| Real | — | $-13.50 | $-16.00 | $-13.00 |
| Estimado | $-8.50 | $-14.83 | $-14.67 | $-14.67 |
| Sorpresa | — | +9.0% | -9.1% | +11.4% |
| Métrica | BCAB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -2965.3% | -38.6% | -2926.6% |
| Net Margin | -2980.3% | -33.6% | -2946.8% |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | -431.1% | -32.0% | -399.1% |
| Current Ratio | 0.37 | 2.84 | -2.47 |
| Debt / Equity | — | 0.28 | — |